



I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in and envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

On: 05/13/2009

By: Crystal Susa Printed: Crystal Susa

| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Complete if Known | | | | |
|--|------------------------|--|-------------------------------|----------------------------------|----------------------------------|-------------------|
| | | Application Number | 10/737,144 | | | |
| | | Filing Date | 12/15/2003 | | | |
| | | First Named Inventor | Yum, et al. | | | |
| | | Group Art Unit | 1618 | | | |
| | | Examiner Name | FUBARA, Blessing M | | | |
| Substitute for form 1449A/PTO | Attorney Docket Number | DURE-050 | | | | |
| Sheet | 1 | Of | 1 | | | |
| U.S. PATENT DOCUMENTS | | | | | | |
| Examiner's Initials | Cite No. | U.S. Patent Document Number | Name of Patentee or Applicant | Date of Publication (MM-DD-YYYY) | | |
| | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | |
| Examiner's Initials | Cite No. | Foreign Patent Document Number | Country | Name of Patentee or Applicant | Date of Publication (MM-DD-YYYY) | Translation (Y/N) |
| /BF/ | 158 | 2008/023261 | WO | Mannion, et al. | 02-28-2008 | N |
| OTHER PRIOR ART | | | | | | |
| Examiner's Initials | Cite No. | AUTHOR, title of article, title of item, date, pages, volume/issue numbers, publisher, city and/or country published | | | | Translation (Y/N) |
| /BF/ | 159 | Cellulose Acetate Butyrate. In: European pharmacopoeia. 4 edn. Strasbourg Cedex, France: Council of Europe; 2001; p. 853-4. | | | | |
| /BF/ | 160 | Gilderman L., et al. "Remoxy™: A New Opioid Drug With Effective Analgesia and Abuse-Resistance." American Pain Society Annual Meeting, San Antonio, TX, May 2006. | | | | |
| /BF/ | 161 | Johnston LD, O'Malley PM, Bachman JG, Schulenberg, JE. "Monitoring the future. National results on adolescent drug use: overview of key findings" (NIH Publication No. 05-5726). Bethesda, MD: National Institute on Drug Abuse 2004. | | | | |
| /BF/ | 162 | Katz NP, et al. "Prescription monitoring of medical and non-medical Schedule II opioid abuse in Massachusetts: 1996-2005." Conference paper presented at the 69th College on Problems of Drug Dependence (CPDD), Quebec, Canada, 2007. | | | | |
| /BF/ | 163 | Meyer RJ, Hussain AS. Awareness topic: mitigating the risk of ethanol induced dose dumping from oral sustained/controlled release dosage forms. In: FDA's Advisory Committee for Pharmaceutical Science Meeting, October 2005. | | | | |
| /BF/ | 164 | Trescot AM, et al. "Opioid Guidelines in the Management of Chronic Non-Cancer Pain." Pain Physician. 2006;9:1-40. | | | | |
| Examiner Signature | /Blessing Fubara/ | | | Date Considered | 6/12/2009 | |

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "Information Disclosure Statement." The right is reserved to antedate any item in accordance with standard procedure.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made of that the cited items are inclusive of all the relevant and material citations that may be available publicly. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the Information Disclosure Statement be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 50-1953.